Skip to main content
Erschienen in: Medical Oncology 2/2018

01.02.2018 | Original Paper

Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters

verfasst von: Lidija Todorović, Boban Stanojević, Vesna Mandušić, Nina Petrović, Vladan Živaljević, Ivan Paunović, Aleksandar Diklić, Vladimir Saenko, Shunichi Yamashita

Erschienen in: Medical Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

A growing body of evidence suggests a role of the von Hippel–Lindau (VHL) tumor suppressor gene in the progression of papillary thyroid carcinoma (PTC). Our previous study of VHL in PTCs showed that lower VHL expression was associated with aggressive tumor features, but we found no evidence for VHL downregulation through common genetic or epigenetic modifications. Several studies pointed to a role of microRNA-92a (miR-92a) in the regulation of VHL expression in different cancers. In the present study, we examined the expression levels of VHL mRNA and miR-92a in 42 pairs of PTCs and matched non-tumor thyroid tissues by means of quantitative RT-PCR. We explored the correlation between them and their association with clinicopathological parameters. The results revealed that both VHL and miR-92a were either up- or downregulated in PTCs compared to corresponding non-tumor tissues. On univariate analysis, lower VHL levels were significantly associated with extrathyroid spread (P = 0.022) and capsular invasion (P = 0.032). Multivariate analysis confirmed the association of low VHL with extrathyroid spread (OR 0.246, 95% CI 0.069–0.872, P = 0.038). Higher miR-92a among PTC tissues associated with the presence of nodal metastases (univariate analysis: P = 0.012; multivariate: OR 4.703, 95% CI 1.109–19.938, P = 0.036). A negative correlation between VHL and miR-92a was observed in a subgroup of PTCs having vascular invasion (P = 0.033, r = − 0.673). The data here reported demonstrate that the expression of both VHL and miR-92a is deregulated in PTC tissues and that in some PTCs they may have opposite roles. These roles, as well as their diagnostic and/or prognostic utility, remain to be clarified.
Literatur
1.
2.
Zurück zum Zitat Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors. Journal of Cancer Epidemiology, 2013: p. 1-10. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors. Journal of Cancer Epidemiology, 2013: p. 1-10.
3.
Zurück zum Zitat Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91(1):313–9.CrossRefPubMed Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91(1):313–9.CrossRefPubMed
4.
Zurück zum Zitat Schlumberger M, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004;150(2):105–12.CrossRefPubMed Schlumberger M, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol. 2004;150(2):105–12.CrossRefPubMed
5.
Zurück zum Zitat Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, et al. Thyroid carcinoma. J Natl Compr Canc Netw. 2010;8(11):1228–74.CrossRefPubMed Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, et al. Thyroid carcinoma. J Natl Compr Canc Netw. 2010;8(11):1228–74.CrossRefPubMed
6.
Zurück zum Zitat Omur O, Baran Y. An update on molecular biology of thyroid cancers. Crit Rev Oncol Hematol. 2014;90(3):233–52.CrossRefPubMed Omur O, Baran Y. An update on molecular biology of thyroid cancers. Crit Rev Oncol Hematol. 2014;90(3):233–52.CrossRefPubMed
7.
Zurück zum Zitat Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742–62.CrossRefPubMed Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007;28(7):742–62.CrossRefPubMed
8.
Zurück zum Zitat Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012. 23 Suppl 7: p. vii110-9. Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 2012. 23 Suppl 7: p. vii110-9.
9.
Zurück zum Zitat Baldini E, Sorrenti S, Tuccilli C, Prinzi N, Coccaro C, Catania A, et al. Emerging molecular markers for the prognosis of differentiated thyroid cancer patients. Int J Surg. 2014;12(Suppl 1):S52–6.CrossRefPubMed Baldini E, Sorrenti S, Tuccilli C, Prinzi N, Coccaro C, Catania A, et al. Emerging molecular markers for the prognosis of differentiated thyroid cancer patients. Int J Surg. 2014;12(Suppl 1):S52–6.CrossRefPubMed
10.
Zurück zum Zitat Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–5.CrossRefPubMed Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271–5.CrossRefPubMed
11.
Zurück zum Zitat Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15(1):55–64.CrossRefPubMed Gossage L, Eisen T, Maher ER. VHL, the story of a tumour suppressor gene. Nat Rev Cancer. 2015;15(1):55–64.CrossRefPubMed
12.
Zurück zum Zitat Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22(24):4991–5004.CrossRefPubMed Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22(24):4991–5004.CrossRefPubMed
13.
Zurück zum Zitat Giles RH, Lolkema MP, Snijckers CM, Belderbos M, van der Groep P, Mans DA, et al. Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene. 2006;25(21):3065–70.CrossRefPubMed Giles RH, Lolkema MP, Snijckers CM, Belderbos M, van der Groep P, Mans DA, et al. Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene. 2006;25(21):3065–70.CrossRefPubMed
14.
Zurück zum Zitat Murria R, Palanca S, de Juan I, Egoavil C, Alenda C, García-Casado Z, et al. Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer. Am J Cancer Res. 2015;5(1):375–85.PubMed Murria R, Palanca S, de Juan I, Egoavil C, Alenda C, García-Casado Z, et al. Methylation of tumor suppressor genes is related with copy number aberrations in breast cancer. Am J Cancer Res. 2015;5(1):375–85.PubMed
15.
Zurück zum Zitat Hasegawa H, Kusumi Y, Asakawa T, Maeda M, Oinuma T, Furusaka T, et al. Expression of von Hippel-Lindau tumor suppressor protein (pVHL) characteristic of tongue cancer and proliferative lesions in tongue epithelium. BMC Cancer. 2017;17(1):381.CrossRefPubMedPubMedCentral Hasegawa H, Kusumi Y, Asakawa T, Maeda M, Oinuma T, Furusaka T, et al. Expression of von Hippel-Lindau tumor suppressor protein (pVHL) characteristic of tongue cancer and proliferative lesions in tongue epithelium. BMC Cancer. 2017;17(1):381.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Koch CA, Brouwers FM, Vortmeyer AO, Tannapfel A, Libutti SK, Zhuang Z, et al. Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer. 2006;6:131.CrossRefPubMedPubMedCentral Koch CA, Brouwers FM, Vortmeyer AO, Tannapfel A, Libutti SK, Zhuang Z, et al. Somatic VHL gene alterations in MEN2-associated medullary thyroid carcinoma. BMC Cancer. 2006;6:131.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Stanojevic B, Saenko V, Todorovic L, Petrovic N, Nikolic D, Zivaljevic V, et al. Low VHL mRNA expression is associated with more aggressive tumor features of papillary thyroid carcinoma. PLoS ONE. 2014;9(12):e114511.CrossRefPubMedPubMedCentral Stanojevic B, Saenko V, Todorovic L, Petrovic N, Nikolic D, Zivaljevic V, et al. Low VHL mRNA expression is associated with more aggressive tumor features of papillary thyroid carcinoma. PLoS ONE. 2014;9(12):e114511.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer—a brief overview. Adv Biol Regul. 2015;57:1–9.CrossRefPubMed Acunzo M, Romano G, Wernicke D, Croce CM. MicroRNA and cancer—a brief overview. Adv Biol Regul. 2015;57:1–9.CrossRefPubMed
19.
Zurück zum Zitat Tetreault N, De Guire V. miRNAs: their discovery, biogenesis and mechanism of action. Clin Biochem. 2013;46(10–11):842–5.CrossRefPubMed Tetreault N, De Guire V. miRNAs: their discovery, biogenesis and mechanism of action. Clin Biochem. 2013;46(10–11):842–5.CrossRefPubMed
20.
Zurück zum Zitat Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–9.CrossRefPubMed Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20(8):460–9.CrossRefPubMed
21.
Zurück zum Zitat Valera VA, Walter BA, Linehan WM, Merino MJ. Regulatory effects of microRNA-92 (miR-92) on VHL gene expression and the hypoxic activation of miR-210 in clear cell renal cell carcinoma. J Cancer. 2011;2:515–26.CrossRefPubMedPubMedCentral Valera VA, Walter BA, Linehan WM, Merino MJ. Regulatory effects of microRNA-92 (miR-92) on VHL gene expression and the hypoxic activation of miR-210 in clear cell renal cell carcinoma. J Cancer. 2011;2:515–26.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Ghosh AK, Cimmino A, Taccioli C, Volinia S, Liu CG, Calin GA, et al. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood. 2009;113(22):5568–74.CrossRefPubMedPubMedCentral Ghosh AK, Cimmino A, Taccioli C, Volinia S, Liu CG, Calin GA, et al. Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood. 2009;113(22):5568–74.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Los M, Jansen GH, Kaelin WG, Lips CJ, Blijham GH, Voest EE. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest. 1996;75(2):231–8.PubMed Los M, Jansen GH, Kaelin WG, Lips CJ, Blijham GH, Voest EE. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest. 1996;75(2):231–8.PubMed
25.
Zurück zum Zitat Hinze R, Boltze C, Meye A, Holzhausen HJ, Dralle H, Rath FW. Expression of the von Hippel-Lindau tumor suppressor gene in nonneoplastic and neoplastic lesions of the thyroid. Endocr Pathol. 2000;11(2):145–55.CrossRefPubMed Hinze R, Boltze C, Meye A, Holzhausen HJ, Dralle H, Rath FW. Expression of the von Hippel-Lindau tumor suppressor gene in nonneoplastic and neoplastic lesions of the thyroid. Endocr Pathol. 2000;11(2):145–55.CrossRefPubMed
26.
Zurück zum Zitat Hunt JL, Yim JH, Tometsko M, Finkelstein SD, Swalsky P, Carty SE. Loss of heterozygosity of the VHL gene identifies malignancy and predicts death in follicular thyroid tumors. Surgery. 2003;134(6):1043–8.CrossRefPubMed Hunt JL, Yim JH, Tometsko M, Finkelstein SD, Swalsky P, Carty SE. Loss of heterozygosity of the VHL gene identifies malignancy and predicts death in follicular thyroid tumors. Surgery. 2003;134(6):1043–8.CrossRefPubMed
27.
Zurück zum Zitat Baldini E, Tuccilli C, Arlot-Bonnemains Y, Chesnel F, Sorrenti S, De Vito C, et al. Deregulated expression of VHL mRNA variants in papillary thyroid cancer. Mol Cell Endocrinol. 2017;443:121–7.CrossRefPubMed Baldini E, Tuccilli C, Arlot-Bonnemains Y, Chesnel F, Sorrenti S, De Vito C, et al. Deregulated expression of VHL mRNA variants in papillary thyroid cancer. Mol Cell Endocrinol. 2017;443:121–7.CrossRefPubMed
28.
Zurück zum Zitat Zia MK, Rmali KA, Watkins G, Mansel RE, Jiang WG. The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells. Int J Mol Med. 2007;20(4):605–11.PubMed Zia MK, Rmali KA, Watkins G, Mansel RE, Jiang WG. The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells. Int J Mol Med. 2007;20(4):605–11.PubMed
29.
Zurück zum Zitat Ma EG, Bai YF, Cao W, Cao Y, Huang YG, Cheng HC, An RH. Cytosine 5-hydroxymethylation regulates VHL gene expression in renal clear cell carcinoma. Oncotarget. 2017;8(38):63780–7.PubMedPubMedCentral Ma EG, Bai YF, Cao W, Cao Y, Huang YG, Cheng HC, An RH. Cytosine 5-hydroxymethylation regulates VHL gene expression in renal clear cell carcinoma. Oncotarget. 2017;8(38):63780–7.PubMedPubMedCentral
30.
Zurück zum Zitat Chen C, Zhou H, Liu X, Liu Z, Ma Q. Reduced expression of von Hippel-Lindau protein correlates with decreased apoptosis and high chondrosarcoma grade. J Bone Joint Surg Am. 2011;93(19):1833–40.CrossRefPubMed Chen C, Zhou H, Liu X, Liu Z, Ma Q. Reduced expression of von Hippel-Lindau protein correlates with decreased apoptosis and high chondrosarcoma grade. J Bone Joint Surg Am. 2011;93(19):1833–40.CrossRefPubMed
31.
Zurück zum Zitat Ren C, Wang W, Han C, Chen H, Fu D, Luo Y, et al. Expression and prognostic value of miR-92a in patients with gastric cancer. Tumor Biol. 2016;37(7):9483–91.CrossRef Ren C, Wang W, Han C, Chen H, Fu D, Luo Y, et al. Expression and prognostic value of miR-92a in patients with gastric cancer. Tumor Biol. 2016;37(7):9483–91.CrossRef
32.
Zurück zum Zitat Tan W, Li Y, Lim SG, Tan TM. miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. World J Gastroenterol. 2014;20(20):5962–72.CrossRefPubMedPubMedCentral Tan W, Li Y, Lim SG, Tan TM. miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma. World J Gastroenterol. 2014;20(20):5962–72.CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Zhao B, Zhu Y, Cui K, Gao J, Yu F, Chen L, et al. Expression and significance of PTEN and miR-92 in hepatocellular carcinoma. Mol Med Rep. 2013;7(5):1413–6.CrossRefPubMed Zhao B, Zhu Y, Cui K, Gao J, Yu F, Chen L, et al. Expression and significance of PTEN and miR-92 in hepatocellular carcinoma. Mol Med Rep. 2013;7(5):1413–6.CrossRefPubMed
34.
Zurück zum Zitat Yu Y, Zhang Y, Zhang S. MicroRNA-92 regulates cervical tumorigenesis and its expression is upregulated by human papillomavirus-16 E6 in cervical cancer cells. Oncol Lett. 2013;6(2):468–74.CrossRefPubMedPubMedCentral Yu Y, Zhang Y, Zhang S. MicroRNA-92 regulates cervical tumorigenesis and its expression is upregulated by human papillomavirus-16 E6 in cervical cancer cells. Oncol Lett. 2013;6(2):468–74.CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Al-Sheikh YA, Ghneim HK, Softa KI, Al-Jobran AA, Al-Obeed O, Mohamed MA, et al. Expression profiling of selected microRNA signatures in plasma and tissues of Saudi colorectal cancer patients by qPCR. Oncol Lett. 2016;11(2):1406–12.CrossRefPubMed Al-Sheikh YA, Ghneim HK, Softa KI, Al-Jobran AA, Al-Obeed O, Mohamed MA, et al. Expression profiling of selected microRNA signatures in plasma and tissues of Saudi colorectal cancer patients by qPCR. Oncol Lett. 2016;11(2):1406–12.CrossRefPubMed
36.
Zurück zum Zitat Wang H, Ke C, Ma X, Zhao Q, Yang M, Zhang W, et al. MicroRNA-92 promotes invasion and chemoresistance by targeting GSK3β and activating Wnt signaling in bladder cancer cells. Tumor Biol. 2016;37(12):16295–304.CrossRef Wang H, Ke C, Ma X, Zhao Q, Yang M, Zhang W, et al. MicroRNA-92 promotes invasion and chemoresistance by targeting GSK3β and activating Wnt signaling in bladder cancer cells. Tumor Biol. 2016;37(12):16295–304.CrossRef
37.
Zurück zum Zitat Jikuzono T, Kawamoto M, Yoshitake H, Kikuchi K, Akasu H, Ishikawa H, et al. The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma. Int J Oncol. 2013;42(6):1858–68.CrossRefPubMedPubMedCentral Jikuzono T, Kawamoto M, Yoshitake H, Kikuchi K, Akasu H, Ishikawa H, et al. The miR-221/222 cluster, miR-10b and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma. Int J Oncol. 2013;42(6):1858–68.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Takakura S, Mitsutake N, Nakashima M, Namba H, Saenko VA, Rogounovitch T, et al. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci. 2008;99(6):1147–54.CrossRefPubMed Takakura S, Mitsutake N, Nakashima M, Namba H, Saenko VA, Rogounovitch T, et al. Oncogenic role of miR-17-92 cluster in anaplastic thyroid cancer cells. Cancer Sci. 2008;99(6):1147–54.CrossRefPubMed
39.
Zurück zum Zitat Smith L, Baxter EW, Chambers PA, Green CA, Hanby AM, Hughes TA, et al. Down-regulation of miR-92 in Breast epithelial cells and in normal but not tumour fibroblasts contributes to breast carcinogenesis. PLoS ONE. 2015;10(10):e0139698.CrossRefPubMedPubMedCentral Smith L, Baxter EW, Chambers PA, Green CA, Hanby AM, Hughes TA, et al. Down-regulation of miR-92 in Breast epithelial cells and in normal but not tumour fibroblasts contributes to breast carcinogenesis. PLoS ONE. 2015;10(10):e0139698.CrossRefPubMedPubMedCentral
40.
Zurück zum Zitat Manni I, Artuso S, Careccia S, Rizzo MG, Baserga R, Piaggio G, et al. The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J. 2009;23(11):3957–66.CrossRefPubMed Manni I, Artuso S, Careccia S, Rizzo MG, Baserga R, Piaggio G, et al. The microRNA miR-92 increases proliferation of myeloid cells and by targeting p63 modulates the abundance of its isoforms. FASEB J. 2009;23(11):3957–66.CrossRefPubMed
41.
Zurück zum Zitat Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 ~ 92 family of miRNA clusters. Cell. 2008;132(5):875–86.CrossRefPubMedPubMedCentral Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 ~ 92 family of miRNA clusters. Cell. 2008;132(5):875–86.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Tili E, Michaille JJ, Liu CG, Alder H, Taccioli C, Volinia S, et al. GAM/ZFp/ZNF512B is central to a gene sensor circuitry involving cell-cycle regulators, TGFβ effectors, Drosha and microRNAs with opposite oncogenic potentials. Nucleic Acids Res. 2010;38(21):7673–88.CrossRefPubMedPubMedCentral Tili E, Michaille JJ, Liu CG, Alder H, Taccioli C, Volinia S, et al. GAM/ZFp/ZNF512B is central to a gene sensor circuitry involving cell-cycle regulators, TGFβ effectors, Drosha and microRNAs with opposite oncogenic potentials. Nucleic Acids Res. 2010;38(21):7673–88.CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Al-Nakhle H, Burns PA, Cummings M, Hanby AM, Hughes TA, Satheesha S, et al. ERβ1 expression is regulated by miR-92 in breast cancer. Can Res. 2010;70(11):4778–84.CrossRef Al-Nakhle H, Burns PA, Cummings M, Hanby AM, Hughes TA, Satheesha S, et al. ERβ1 expression is regulated by miR-92 in breast cancer. Can Res. 2010;70(11):4778–84.CrossRef
44.
Zurück zum Zitat Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA. 2006;103(24):9136–41.CrossRefPubMedPubMedCentral Zhang L, Huang J, Yang N, Greshock J, Megraw MS, Giannakakis A, et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci USA. 2006;103(24):9136–41.CrossRefPubMedPubMedCentral
45.
Zurück zum Zitat Wang L, Wu J, Xie C. miR-92a promotes hepatocellular carcinoma cells proliferation and invasion by FOXA2 targeting. Iran J Basic Med Sci. 2017;20(7):783–90.PubMedPubMedCentral Wang L, Wu J, Xie C. miR-92a promotes hepatocellular carcinoma cells proliferation and invasion by FOXA2 targeting. Iran J Basic Med Sci. 2017;20(7):783–90.PubMedPubMedCentral
Metadaten
Titel
Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters
verfasst von
Lidija Todorović
Boban Stanojević
Vesna Mandušić
Nina Petrović
Vladan Živaljević
Ivan Paunović
Aleksandar Diklić
Vladimir Saenko
Shunichi Yamashita
Publikationsdatum
01.02.2018
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2018
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-017-1066-3

Alter verschlechtert Prognose bei Endometriumkarzinom

11.05.2024 Endometriumkarzinom Nachrichten

Ein höheres Alter bei der Diagnose eines Endometriumkarzinoms ist mit aggressiveren Tumorcharakteristika assoziiert, scheint aber auch unabhängig von bekannten Risikofaktoren die Prognose der Erkrankung zu verschlimmern.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.